United States Patent 6,165,497 (Nicotine Transdermal Device): Scope, Claim Architecture, and Patent Landscape
What is the claimed invention in US 6,165,497?
US 6,165,497 claims a nicotine transdermal delivery system built around three structural elements in one delivery pathway from a nicotine reservoir to the skin:
- Nicotine reservoir means: nicotine is dissolved in a solvent at a concentration less than saturation, with enough nicotine to support delivery at 250 to 4000 μg/hr for a substantial portion of the administration period.
- Nicotine release rate controlling membrane means: positioned in the path of nicotine migration and configured to maintain an administration rate substantially constant in the 250 to 4000 μg/hr range for a substantial portion of the period.
- Adhesive means: placed in the path of nicotine migration from the rate controlling membrane to the skin.
The claim set then tightens performance and material parameters using:
- Thermodynamic activity of nicotine in the reservoir and adhesive layers (activity caps and ranges).
- Steady state flux constraints.
- Patch architecture definitions (reservoir layer, occlusive backing, and rate controlling membranes).
- Method of use via application to an individual.
The core commercial target is a nicotine patch that maintains predictable delivery over 8 hours and up to 16 hours (claim language uses “8 hours or more” and “at least 16 hours”), with bounded average or steady flux depending on claim.
How broad is the claim scope?
Independent claim 1 sets the outer perimeter
Claim 1 is the broadest independent claim provided in the text. It defines scope through functional and quantitative constraints tied together:
- Administration period: “predetermined nicotine administration period of at least about eight hours.”
- Administration rate: 250 to 4000 μg/hr, maintained “substantially constant” for “a substantial portion” of the period.
- Reservoir formulation constraint: nicotine is dissolved in solvent at concentration less than saturation.
- Reservoir capacity constraint: reservoir contains sufficient nicotine to deliver at the specified administration rate range.
- Membrane constraint: release rate controlling membrane in the nicotine migration path and maintaining the rate window.
- Adhesive constraint: adhesive in the nicotine migration path.
This combination narrows the class of devices to those where rate control is achieved through a specific layered arrangement that includes both a rate controlling membrane and an adhesive acting within the nicotine migration path.
Dependent claims narrow by testable physicochemical thresholds
Dependent claims introduce specific measurable parameters that materially reduce design freedom:
- Claim 2: initial equilibrated thermodynamic activity of nicotine in the reservoir is ≤ 0.50.
- Claim 5: activity in the reservoir and adhesive layers is 0.20 to 0.40.
- Claim 3: adhesive has high nicotine solubility.
- Claim 4: at least 50% of initial nicotine loading is in the reservoir.
- Claim 6: steady state flux is 23 μg/cm² hr.
- Claim 7: duplicates claim 6.
These features create a claim set that is likely optimized around a specific physicochemical delivery regime (thermodynamic activity and solubility profile) tied to flux stability.
Claims 8 to 11 reframe the architecture with patch-style language
Claims 8 and 9 define “A transdermal patch comprising” using a classic reservoir/occlusive backing/rate-controlling membrane framework. These claims add or change performance bounds:
- Claim 8 (16-hour oriented):
- reservoir supports useful flux for at least 16 hours
- occlusive backing layer over the reservoir on the skin-distal side
- average transdermal flux over the time period is below 200 μg/cm²/hr
- Claim 9 (8-hour oriented):
- reservoir supports useful flux for 8 hours or more
- occlusive backing layer present
- nicotine permeable rate controlling membrane controls diffusion “from said skin-facing side” at a flux between 23 and 800 μg/cm²/hr for 8 hours or more
- Claims 10 and 11 are methods mirroring claims 8 and 9.
Claims 12 and 13 add flux window on a steady-state portion
- Claim 12: steady state flux during the steady state portion is 30 to 120 mg/cm²/hr (note: the units as written appear to conflict with earlier μg/cm²/hr style flux in claim 9; the numerical magnitude may be a drafting/unit issue in the claim text provided).
- Claim 13: method claim equivalent of claim 12.
Even with the unit ambiguity, these claims function as additional numeric filters on acceptable delivery profiles.
What is the practical “design map” implied by the claims?
The claim language forces a delivery system where nicotine flux and rate are stabilized by controlling:
- Driving force (nicotine thermodynamic activity in reservoir/adhesive)
- Mass transport resistance (rate controlling membrane diffusion)
- Skin-side partitioning and migration path (adhesive positioned in the nicotine migration path)
- Overall dose capacity and packaging (sufficient nicotine for 8 or 16-hour spans)
- Backside boundary condition (occlusive backing layer)
A company designing around the claim would focus on whether the system:
- maintains 250 to 4000 μg/hr administration rate substantially constant for at least ~8 hours,
- uses a release rate controlling membrane and adhesive means arranged in the nicotine migration path, and
- meets activity and flux constraints if those dependent claims are asserted.
Claim-by-claim scope breakdown (what each claim covers)
Claims 1-7: Device with nicotine reservoir + rate controlling membrane + adhesive in migration path
| Claim |
Key limitations that define infringement-relevant scope |
What it narrows |
| 1 |
Predetermined period ≥ about 8 hours; administration rate 250-4000 μg/hr substantially constant for substantial portion; nicotine dissolved in solvent at concentration < saturation; reservoir amount sufficient; release rate controlling membrane in nicotine migration path maintains administration rate; adhesive in nicotine migration path |
Core structural and performance envelope |
| 2 |
Nicotine activity in reservoir after equilibration ≤ 0.50 |
Restricts reservoir formulation thermodynamics |
| 3 |
Adhesive has high nicotine solubility |
Requires adhesive selection that supports partitioning |
| 4 |
At least 50% of initial nicotine loading is in reservoir |
Forces distribution of nicotine within layers |
| 5 |
Nicotine activity in reservoir and adhesive layers is 0.20-0.40 |
Tightens to a mid-range activity band |
| 6 |
Steady state flux equals 23 μg/cm² hr |
Locks flux to a specific steady value |
| 7 |
Repeats claim 6 |
No additional narrowing beyond claim 6 |
Claims 8-13: Patch architecture with occlusive backing and rate control via nicotine-permeable membrane
| Claim |
Key limitations |
What it narrows |
| 8 |
Total time ≥ 16 hours; reservoir sufficient for useful transdermal flux; occlusive backing on skin-distal side; average transdermal flux over time < 200 μg/cm²/hr |
Time span + average flux upper bound |
| 9 |
Total time ≥ 8 hours; reservoir sufficient; occlusive backing; membrane controls diffusion from skin-facing side to flux 23-800 μg/cm²/hr for ≥ 8 hours |
Time span + flux window |
| 10 |
Method using a patch meeting claim 8 |
Use infringement aligned to claim 8 device |
| 11 |
Method using a patch meeting claim 9 |
Use infringement aligned to claim 9 device |
| 12 |
Steady-state flux portion: 30-120 mg/cm²/hr (as stated) |
Numeric steady-state window (unit issue in provided text) |
| 13 |
Method equivalent of claim 12 |
Use aligned to claim 12 window |
Where are the highest-risk infringement hooks?
1) Substantially constant administration rate (250-4000 μg/hr) for at least ~8 hours
This combination is specific enough that a competitor can be at risk if their patch:
- targets nicotine in that delivery-rate window,
- maintains near-constant release for a large portion of the period, and
- includes both a release controlling membrane and adhesive positioned in the nicotine migration path.
2) Thermodynamic activity constraints
Claims 2 and 5 are formulation-level hooks. Even if a patch matches the structural arrangement, failing the nicotine activity window may defeat these dependent claims.
3) Flux constraints and steady-state targeting
Claims 6 and 9 use explicit flux ranges/values, which tend to be measured during development and stability qualification. Any patch aiming at a steady flux near 23 μg/cm²/hr or an average flux constraint under 200 μg/cm²/hr over 16 hours may collide.
4) Layer allocation of nicotine loading
Claim 4 requires that at least 50% of initial nicotine loading is in the reservoir. Many designs keep nicotine distributed across functional layers; that design difference can matter.
How the claims interact: likely assertion patterns
Based on the architecture, a plausible enforcement path is:
- Use claim 1 as the primary structural/performance claim.
- Assert dependent claims where the accused product’s test data align:
- nicotine activity profile (claims 2 and 5),
- adhesive solubility (claim 3),
- nicotine loading distribution (claim 4),
- steady state flux matching (claims 6 and/or 12 if units are interpreted as written).
If an accused patch is more aligned to classic reservoir/occlusive backing architectures, claims 8-11 provide an alternate independent route (device and method).
Patent landscape: what US 6,165,497 likely sits against
Context: nicotine transdermal delivery is a crowded design space
Nicotine transdermal products have long relied on:
- reservoir systems,
- rate controlling membranes,
- adhesives optimized for nicotine partitioning,
- backing layers to control evaporative losses and diffusion boundaries.
In the landscape around this patent type, common contested themes include:
- rate control mechanisms,
- stabilization of flux over wear time,
- nicotine activity/solubility management to reduce initial burst or late-stage decline,
- optimization of patch size and dosing for consistent exposure.
Where design-around is most feasible
Given the specific numerical windows, “escape” generally comes from at least one of these pivots:
- delivery-rate window outside 250-4000 μg/hr substantially constant for a substantial portion of ≥8 hours,
- different layer architecture where adhesive is not positioned as part of the nicotine migration path (as claimed),
- thermodynamic activity outside ≤0.50 (claim 2) or outside 0.20-0.40 (claim 5),
- flux targets outside claim ranges (notably 23 μg/cm²/hr for claim 6 or average <200 μg/cm²/hr over 16 hours for claim 8).
Where “adjacent” competitors may overlap
Competitors pursuing patches that are:
- stabilized to deliver consistent nicotine flux for 8 to 24 hours,
- built with occlusive backings and nicotine permeable rate controlling membranes,
- tuned via nicotine activity and adhesive partitioning,
tend to converge on similar performance and characterization metrics that appear in this claim set.
Business impact: what matters to R&D and diligence
Product development
If a nicotine patch aims for 16-hour dosing with average flux under 200 μg/cm²/hr, it maps directly to claim 8. If it targets 8-hour dosing with a flux window 23-800 μg/cm²/hr, it maps directly to claim 9.
If a patch is tuned to a specific steady-state flux, the 23 μg/cm²/hr limitation in claim 6 is a direct collision point if matched.
Freedom-to-operate triage
In diligence, the highest-effort data to test against this patent are:
- measured administration rate over time (μg/hr) and constancy criteria,
- nicotine activity in reservoir and adhesive layers after equilibration,
- adhesive nicotine solubility characterization,
- distribution of nicotine loading by layer,
- measured steady-state flux and average flux over the defined wearing period,
- proof that adhesive sits in the nicotine migration path as characterized in the claims.
Key Takeaways
- US 6,165,497 claims a nicotine transdermal system defined by a reservoir (nicotine in sub-saturation solvent), a rate-controlling membrane maintaining 250 to 4000 μg/hr substantially constant for ≥ about 8 hours, and an adhesive positioned in the nicotine migration path.
- The most material claim narrowing comes from nicotine thermodynamic activity limits (≤0.50; 0.20-0.40), steady-state flux (notably 23 μg/cm²/hr), and nicotine loading distribution (≥50% in reservoir).
- Claims 8-11 reframe scope as a classic nicotine patch with reservoir + occlusive backing + nicotine permeable rate controlling membrane, with time/flux bounds for 8 hours and 16 hours designs.
- For patent landscape positioning, the enforcement risk concentrates where competitors tune release profiles using activity/solubility and membrane-controlled diffusion to achieve stable nicotine flux over extended wear times.
FAQs
What does “substantially constant” mean for claim 1 infringement risk?
It is tied to maintaining the administration rate within 250-4000 μg/hr for a “substantial portion” of a period of at least about eight hours, so the product’s time-course profile matters more than a single point measurement.
Which dependent claims add the most measurable formulation constraints?
Claims 2, 3, 4, and 5: nicotine activity in reservoir/adhesive layers, adhesive nicotine solubility, and nicotine loading distribution.
Do claims 8 and 9 cover the same design center as claim 1?
They cover overlapping patch structures but express the constraints as patch architecture plus average/steady flux windows over 16 hours (claim 8) and 8 hours (claim 9).
Is there a direct “flux window” collision for steady-state designs?
Yes. Claim 6 targets a steady-state flux of 23 μg/cm²/hr; claim 9 includes a flux window 23-800 μg/cm²/hr for ≥8 hours.
How should a diligence team prioritize testing against this patent?
Prioritize: time-course administration rate (μg/hr), nicotine activity in reservoir/adhesive layers, adhesive solubility and loading distribution, and measured flux (steady and average) over the claimed durations.
References
- United States Patent 6,165,497. (Claims excerpt provided in prompt).
